{"id":14270,"date":"2025-01-27T00:20:35","date_gmt":"2025-01-27T00:20:35","guid":{"rendered":"http:\/\/torontotribune.ca\/index.php\/2025\/01\/27\/us-fda-approves-monthly-maintenance-dosing-for-biogen-eisai-alzheimers-drug-by-investing-com\/"},"modified":"2025-01-27T00:20:35","modified_gmt":"2025-01-27T00:20:35","slug":"us-fda-approves-monthly-maintenance-dosing-for-biogen-eisai-alzheimers-drug-by-investing-com","status":"publish","type":"post","link":"https:\/\/torontotribune.ca\/index.php\/2025\/01\/27\/us-fda-approves-monthly-maintenance-dosing-for-biogen-eisai-alzheimers-drug-by-investing-com\/","title":{"rendered":"US FDA approves monthly maintenance dosing for Biogen\/Eisai Alzheimer\u2019s drug By Investing.com"},"content":{"rendered":"


\n<\/p>\n

\n
\n

Investing.com– The U.S. Food and Drug Administration approved monthly maintenance dosing for an Alzheimer\u2019s drug developed by Japan\u2019s Eisai Co., Ltd. <\/span><\/span> <\/span><\/span> (TYO:) and U.S. partner Biogen (NASDAQ:), the two said on Monday.<\/p>\n

The approval allows patients to receive a monthly dose of the drug, Leqmbi, after receiving an intravenous infusion of the drug every two weeks for 18 months, Eisai and Biogen said in a joint statement. Patients can also continue to dose once every two weeks.<\/p>\n

Leqembi received standard FDA approval in 2023 after it showed progress in slowing cognitive decline in Alzheimer\u2019s patients.\u00a0<\/p>\n

Last year, a rival drug from Eli Lilly (NYSE:), Kisunla, was approved by the FDA. Kisunla is administered once a month and can be stopped after substantial progress in curbing the disease.\u00a0<\/p>\n

Both drugs target deposits of a protein called amyloid beta in the brain, which has been linked to Alzheimer\u2019s disease. Leqembi requires maintenance dosing to prevent future amyloid buildup.\u00a0<\/p>\n<\/div>\n<\/div>\n